Treatment
Treatment A clinical trials
We’re tracking 8,322 recruiting studies that include Treatment A, each written for real people, not researchers, below.
Recruiting studies
- NCT07010484Recruiting
New imaging tests for polymyalgia rheumatica
This trial tests if new imaging methods can help diagnose and treat polymyalgia rheumatica (PMR). It may be for you if you're over 50, have pain in your shoulders or hips, and haven't taken steroids for PMR in the last 2 months.
AarhusAges 50 years+ - NCT07007052RecruitingPhase 2
Tagraxofusp plus venetoclax for newly diagnosed BPDCN
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
AmiensAges 18 years+ - NCT07007949RecruitingPhase 2
New drug combo for adult AML with IDH1 mutation
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
Suzhou, JiangsuAges 18 years+ - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07010939Recruiting
Side effects and quality of life after breast cancer treatment in China
This study looks at how local treatments like surgery, chemotherapy, radiation, hormone therapy, or targeted therapy affect your side effects and quality of life. Researchers want to learn from women with early-stage breast cancer to improve care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07010237RecruitingPhase 2
Lower-dose immune therapy plus hetrombopag for older adults with severe aplastic anemia
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Tianjin, Tianjin MunicipalityAges 65 years+ - NCT07013292Recruiting
Omaveloxolone for swallowing issues in Friedreich's ataxia
This study looks at whether omaveloxolone (a medication) can help improve swallowing problems in people with Friedreich's ataxia. If you have been taking omaveloxolone for at least 6 months, your data may help researchers understand if it helps with swallowing.
Nice, Alpes MaritimesAges 16 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07004244RecruitingPhase 1
KRAS vaccine study for people with KRAS-mutated cancers
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Chengdu, SichuanAges 18 years+ - NCT07003386RecruitingPhase 2/Phase 3
Galantamine for recent ischemic stroke
This trial tests a plant-based medicine called galantamine, given within 3 days of an ischemic stroke, to see if it helps recovery. It combines Western and Traditional Chinese Medicine approaches and aims to understand how the treatment works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT06831175RecruitingPhase 2
PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Chengdu, SichuanAges 18–70 - NCT07002684Recruiting
Esketamine study for depression
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
ZagrebAges 18–70 - NCT04561661Recruiting
Pinning versus splinting for finger fractures
This study compares two ways to treat certain finger bone fractures: using a small pin through the skin or using a splint. It also looks at early movement to help prevent stiffness and improve hand function.
StockholmAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT05921305RecruitingPhase 3
Low-dose methotrexate plus steroid for early acute GVHD
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Beijing, Beijing MunicipalityAges 15–65 - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06995729RecruitingPhase 1
Testing zavegepant nasal spray in children with migraines
This trial tests whether the medicine zavegepant (given as a nasal spray) is safe and works well for children aged 6 to 11 who have a history of migraines. If your child gets migraines, this study may help find a new treatment option.
Washington D.C., District of ColumbiaAges 6–11 - NCT06998680Recruiting
Chinese herbs for hair loss and gray hair
This trial tests if Chinese herbal treatments can reduce hair loss and reverse gray hair over 6 months. It may help adults who have thinning hair or graying, as long as they haven't dyed or permed their hair recently.
Xiangtan, HunanAges 18–60 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06846489RecruitingPhase 2
Acalabrutinib plus rituximab for untreated mantle cell lymphoma
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT06994975RecruitingPhase 3
Stroke drug test for patients who missed the 4.5 hour window
This trial tests a clot-busting drug for people who had a stroke more than 4.5 hours ago. It uses a special CT scan to see if the treatment can still help them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07002112RecruitingPhase 1
A trial of a dual-target CAR-T therapy for blood cancers
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
Hefei, AnhuiAges 18 years+
Common questions
- Are there clinical trials studying Treatment A?
- Yes. Clin2 currently lists 8,322 recruiting studies that include Treatment A, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Treatment A trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Treatment A an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Treatment A or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.